Page 1 od 17 rezultati
BACKGROUND OF THE INVENTION
This disclosure relates to combinations of soluble .beta.-glucan and anti-cancer agents that affect the tumor microenvironment, including immunosuppression-relieving anti-cancer agents. .beta.-glucan is a fungal PAMP and is recognized by pattern recognition molecule C3 in
BACKGROUND OF THE INVENTION
The present invention relates to combinations of soluble .beta.-glucan and anti-cancer agents that affect the tumor microenvironment, including immunosuppression-relieving anti-cancer agents. .beta.-glucan is a fungal PAMP and is recognized by pattern recognition molecule
BACKGROUND OF THE INVENTION
Beta(.beta.)-glucan is a complex carbohydrate, generally derived from several sources, including yeast, bacteria, fungi and cereal grains. Each type of .beta.-glucan has a unique structure in which glucose is linked together in different ways, resulting in different
BACKGROUND OF THE INVENTION
Beta(.beta.)-glucan is a complex carbohydrate, generally derived from several sources, including yeast, bacteria, fungi and cereal grains. Each type of .beta.-glucan has a unique structure in which glucose is linked together in different ways, resulting in different
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to radiodiagnostic agents and reagents for preparing such agents, and also methods for producing radiolabeled radiodiagnostic agents. Specifically, the invention relates to technetium-99m (.sup.99m Tc) labeled agents,
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims priority benefits to Chinese Patent Application No. 200810105513.3 filed on Apr. 29, 2008, the contents of which are incorporated herein by reference.
BACKGROUND OF THE INVENTION
1. Field of the Invention
The invention relates to a
SUMMARY
This disclosure describes, in one aspect, a composition that includes a .beta.-glucan component and an antibody component that specifically binds to the .beta.-glucan. In some embodiments, the .beta.-glucan may be derived from yeast. In some embodiments, the .beta.-glucan can include a
BACKGROUND OF THE INVENTION
Technical Field
The present invention relates to a liposome for treating cancer by including doxorubicin, a polyunsaturated fatty acid, and beta glucan in combination.
Description of the Related Art
The "background" description provided herein is for the purpose of
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to radiodiagnostic agents and reagents for preparing such agents, and also methods for producing radiolabeled radiodiagnostic agents. Specifically, the invention relates to technetium-99m (.sup.99m Tc) labeled agents,
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to radiodiagnostic agents and reagents for preparing such agents, and also methods for producing radiolabeled radiodiagnostic agents. Specifically, the invention relates to technetium-99m (.sup.99m Tc) labeled agents,
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to radiodiagnostic agents and reagents for preparing such agents, and also methods for producing radiolabeled radiodiagnostic agents. Specifically, the invention relates to technetium-99m (.sup.99m Tc) labeled agents,
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to a biologically active substance recovered from the mycelium and fruit body of Agaricus blazei; and a process of preparing the biologically active substance.
2. Description of the Prior Art
Agaricus blazei is a
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to a biologically active substance recovered from the mycelium and fruit body of Agaricus blazei; and a process of preparing the biologically active substance.
2. Description of the Prior Art
Agaricus blazei is a
Throughout this application, various references are cited. Disclosures of these publications in their entireties are hereby incorporated by reference into this application to more fully describe the state of the art to which this invention pertains.
BACKGROUND OF THE INVENTION
Beta-glucans have been
Throughout this application, various references are cited. Disclosures of these publications in their entireties are hereby incorporated by reference into this application to more fully describe the state of the art to which this invention pertains.
BACKGROUND OF THE INVENTION
Monoclonal antibodies